7Baggers

Evoke Pharma, Inc
(NASDAQ:EVOK) 

EVOK stock logo

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat sym...

Founded: 2007
Full Time Employees: 5
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2017-12-31 2016-12-31 2015-12-31 2014-12-31 2013-12-31 
                                   
      net product sales
    		2,654,186 2,551,366 1,735,490 1,675,994 1,562,860 1,131,368 810,408 796,370 832,100 461,795 418,380 360,571 930,449 236,635 90,421                 
      operating expenses:
    		                               
      cost of goods sold
    		104,024 41,478 92,529 59,024 34,908 57,357 50,591 190,084 89,775 67,774 22,760 136,679 58,435 68,253 64,751                 
      research and development
    		11,677  4,645 22,560  92,357 66,990 27,207 40,388 191,478 41,717 35,723 81,699 195,229 277,825 103,846 205,032 5,782,094 463,853 641,542 822,444 1,205,599 746,882 695,360 625,497 1,388,791      
      selling, general and administrative
    		3,824,142 3,733,450 3,139,536 3,482,328 3,131,389 2,766,077 2,847,940 2,288,861 2,614,488 2,315,175 2,405,075 1,735,524 2,635,161 2,142,149 2,338,295                 
      total operating expenses
    		3,939,843 3,774,928 3,236,710 3,563,912 3,166,297 2,915,791 2,965,521 2,506,152 2,744,651 2,574,427 2,469,552 1,907,926 2,775,295 2,405,631 2,680,871 2,232,106 2,079,610 6,964,966 1,793,687 1,424,158 1,636,662 2,123,738 1,969,895 1,768,420 1,522,557 2,306,096      
      income from operations
    		-1,285,657 -1,223,562 -1,501,220 -1,887,918 -1,603,437 -1,784,423 -2,155,113 -1,709,782 -1,912,551 -2,112,632 -2,051,172 -1,547,355 -1,844,846 -2,168,996 -2,590,450 -2,209,086 -2,079,610 -6,964,966 -1,793,687 -1,424,158 -1,636,662 -2,123,738 -1,969,895 -1,768,420 -1,522,557 -2,306,096      
      yoy
    		-19.82% -31.43% -30.34% 10.42% -16.16% -15.54% 5.07% 10.50% 3.67% -2.60% -20.82% -29.95% -11.29% -68.86% 44.42% 55.12% 27.06% 227.96% -8.95% -19.47% 7.49% -7.91%          
      qoq
    		5.07% -18.50% -20.48% 17.74% -10.14% -17.20% 26.05% -10.60% -9.47% 3.00% 32.56% -16.13% -14.94% -16.27% 17.26% 6.23% -70.14% 288.30% 25.95% -12.98% -22.93% 7.81% 11.39% 16.15% -33.98%       
      other income:
    		                               
      interest income
    		99,294 81,001 46,058 26,544 35,558 41,164 35,331 32,588 24,714 3,910 795 1,019 1,421 3,011 3,164 776 1,033 485 3,378 5,930 8,597 9,642 4,629 7,788 3,089 2,903      
      interest expense
    		-126,027 -124,657 -124,658 -126,027 -126,028 -124,658 -123,288 -126,027 -126,027 -124,658 -123,288 -126,026 -126,027 -124,658 -123,339 -59,552 -50,528 -2,914              
      total other income
    		-26,733 -43,656 -78,600     -93,439 -101,313 -120,748 -122,493 -125,007 -124,606 -121,647 -15,045 -58,776 -49,495 -2,429 3,378 5,930 8,597 9,642 4,629 7,788 3,089 2,903      
      net income
    		-1,312,390 -1,267,218 -1,579,820 -1,987,401 -1,693,907 -1,867,917 -2,243,070 -1,803,221 -2,013,864 -2,233,380 -2,173,665 -1,672,362 -1,969,452 -2,290,643 -2,605,495 -2,267,862 -2,129,105 -6,967,395 -1,790,309 -1,418,228 -1,628,065 -2,114,096 -1,965,266 -1,760,632 -1,519,468 -2,303,193      
      yoy
    		-22.52% -32.16% -29.57% 10.21% -15.89% -16.36% 3.19% 7.82% 2.26% -2.50% -16.57% -26.26% -7.50% -67.12% 45.53% 59.91% 30.78% 229.57% -8.90% -19.45% 7.15% -8.21%          
      qoq
    		3.56% -19.79% -20.51% 17.33% -9.32% -16.72% 24.39% -10.46% -9.83% 2.75% 29.98% -15.08% -14.02% -12.08% 14.89% 6.52% -69.44% 289.17% 26.24% -12.89% -22.99% 7.57% 11.62% 15.87% -34.03%       
      net income per share
    		-0.94 -0.93 -0.17 -0.59 -0.51 -0.56 -0.67 -0.53 -0.6 -0.71 -0.07 -0.06 -0.06 -0.07 -0.08 -0.09 -0.08 -0.28 -0.07 -0.06 -0.07 -0.09 -0.11 -0.1 -0.09 -0.14      
      weighted-average shares used for eps calculation
    		1,399,882 1,363,525 9,082,139 3,343,070 3,343,070 3,343,070 3,343,070 3,143,626 3,343,070 3,156,925 32,777,294 32,185,758 32,542,481 32,386,004 31,158,065 25,492,169 26,146,220 24,987,975 24,439,881 22,296,089 24,128,060 23,258,567 17,484,318 16,602,422 17,129,649 16,425,468      
      total other
    		   -65,480.25 -90,470 -83,494 -87,957                         
      forgiveness of paycheck protection loan and accrued interest
    		              105,130                 
      general and administrative
    		               1,096,821 1,874,578 1,182,872 1,329,834 782,616 814,218 918,139 1,223,013 1,073,060 897,060 917,305      
      gain from change in fair value of warrant liability
    		                               
      change in fair value of warrant liability
    		                       108,348        
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2017-12-31 2016-12-31 2015-12-31 2014-12-31 2013-12-31 
                                     
        assets
      		                               
        current assets:
      		                               
        cash and cash equivalents
      		11,339,032 9,177,836 9,702,755 4,739,426 5,964,826 7,006,431 8,212,804 9,843,699 12,350,024 13,450,949 7,701,201 9,144,710 11,141,908 16,720,939 18,185,974 8,068,939 6,280,656 7,990,392 4,133,188 5,663,833 6,504,802 7,440,079 4,028,550 5,319,004 6,567,918 6,531,079 7,679,267 9,007,071 8,691,155 14,155,809 24,196,691 
        accounts receivable
      		2,022,518 2,003,003 1,451,904 673,071 1,233,904 1,023,813 687,302 624,832 674,970 365,643 418,910 295,193 222,166 198,411 127,795 23,311                
        prepaid expenses
      		146,704 382,936 704,215 885,040 37,855 371,348 671,386 952,954  307,919 615,832 923,746  307,254 614,508 921,762 336,432 193,902 387,803 581,706 775,607 109,739 219,479 329,218 438,957 83,682 251,046 267,711 833,276 931,461 234,262 
        inventories
      		493,408 544,765 588,776                             
        other current assets
      		36,421 27,675 6,312 47,532 98,094 11,551 11,551 11,551 11,551 11,551 11,551 11,551 11,551 11,703 11,703 30,300 11,551 11,551 11,551  11,551 11,551 11,551   11,551  7,997  161,436  
        total current assets
      		14,038,083 12,136,215 12,453,962 6,826,909 7,839,604 8,926,855 9,947,910 11,722,414 13,256,849 14,404,396 9,026,270 10,560,734 11,600,842 17,472,348 19,176,024 9,280,792 6,714,784 8,195,845 4,532,542 6,245,539 7,291,960 7,561,369 4,259,580 5,648,222 7,006,875 6,626,312 7,930,313 9,282,779 9,524,431 15,248,706 24,430,953 
        deferred offering costs
      		115,488   241,637                            
        total assets
      		14,153,571 12,136,215 12,453,962 7,068,546 7,852,974 8,979,697 10,039,307 11,851,488 13,410,520 14,404,396 9,026,270 10,573,162 11,649,959 17,557,281 19,295,950 9,434,048 6,750,899 8,267,056 4,637,894 6,395,628 7,327,358 7,631,164 4,362,832 5,659,773 7,018,426 6,626,312 7,941,864 9,294,330 9,532,428 15,301,729 24,986,458 
        liabilities and stockholders' equity
      		                               
        current liabilities:
      		                               
        accounts payable and accrued expenses
      		2,188,164 2,183,850 1,953,959 1,711,778 1,397,442 1,415,309 1,185,925 934,312 1,020,690 824,481 944,478 874,028 530,528 519,001 691,225 1,273,572 765,603 604,832 925,628 1,033,383 1,154,520 407,517 491,831 476,202 625,994 441,085 1,048,927 478,223 927,606 1,011,629 284,915 
        accrued compensation
      		590,634 425,797 265,881 1,324,010 829,669 612,932 400,251 591,158 716,993 528,665 412,198 519,317 810,790 621,476 428,794 1,016,232 715,423 860,521 685,266 843,162 964,243 807,706 692,304 1,158,251 984,683 824,849 1,025,911 933,450 760,782 697,245 557,399 
        note payable
      		5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 2,000,000 2,000,000              
        accrued interest payable
      		1,987,637 1,861,610 1,736,953 1,612,295 1,486,268 1,360,240 1,235,583 1,112,295 986,268 860,240 735,583 612,295 486,268 360,240 235,583 112,994 53,005               
        total current liabilities
      		9,766,435 9,471,257 8,956,793 3,035,788 2,240,481 2,081,083 1,677,573 1,654,544 1,877,983 1,353,146 1,356,676 1,405,773 1,390,435 6,231,435 6,248,983 7,535,677 6,621,309 6,640,732 1,716,246 2,015,083 2,154,161 1,285,018 1,287,387 1,634,453 1,610,677 1,265,934 2,074,838 1,411,673 1,834,440 1,871,617 2,284,906 
        total liabilities
      		9,766,435 9,471,257 8,956,793 9,648,083 8,726,749 8,441,323 7,913,156 7,766,839 7,877,622 7,213,386 7,092,259 7,018,068 6,876,703 11,591,675 11,484,566 12,648,671 8,674,314 8,640,732      1,634,453 1,610,677 1,265,934 5,776,115 5,506,692 6,067,499 6,113,065 3,803,197 
        commitments and contingencies
      		                               
        stockholdersʼ equity
      		                               
        preferred stock, 0.0001 par value...
      		                               
        common stock, 0.0001 par value...
      		89 73 859 334 334 334 334 334 334 334 3,292 3,266 3,266 3,244 3,237 2,662 2,633 2,601 2,446 2,443 2,423 2,411 1,788 1,743 1,743 1,690 1,541 1,235 720 611 610 
        additional paid-in capital
      		131,985,913 128,951,361 128,515,568 120,859,567 120,577,928 120,296,170 120,016,030 119,731,458 119,376,486 119,020,734 111,527,397 110,974,841 110,520,641 109,743,561 109,298,703 95,667,776 94,691,151 94,111,817 90,439,901 90,108,492 89,482,936 89,027,832 83,643,658 82,628,312 82,250,109 80,683,323 73,202,863 62,595,546 51,524,821 45,127,202 43,874,119 
        accumulated deficit
      		-127,598,866 -126,286,476 -125,019,258 -123,439,438 -121,452,037 -119,758,130 -117,890,213 -115,647,143 -113,843,922 -111,830,058 -109,596,678 -107,423,013 -105,750,651 -103,781,199 -101,490,556 -98,885,061 -96,617,199 -94,488,094 -87,520,699 -85,730,390 -84,312,162 -82,684,097 -80,570,001 -78,604,735 -76,844,103 -75,324,635 -71,038,655 -58,809,143 -48,060,612 -35,939,149  
        total stockholdersʼ equity
      		4,387,136 2,664,958                              
        total liabilities and stockholders' equity
      		14,153,571 12,136,215 12,453,962 7,068,546 7,852,974 8,979,697 10,039,307 11,851,488 13,410,520 14,404,396 9,026,270 10,573,162 11,649,959 17,557,281    8,267,056 4,637,894 6,395,628 7,327,358 7,631,164 4,362,832 5,659,773 7,018,426 6,626,312 7,941,864 9,294,330 9,532,428 15,301,729  
        stockholders' equity
      		                               
        total stockholders' equity
      		  3,497,169 -2,579,537 -873,775 538,374 2,126,151 4,084,649 5,532,898 7,191,010 1,934,011 3,555,094 4,773,256 5,965,606    -373,676 2,921,648 4,380,545 5,173,197 6,346,146 3,075,445 4,025,320 5,407,749 5,360,378 2,165,749 3,787,638 3,464,929 9,188,664  
        inventory
      		   481,840 504,925 513,712 364,867 289,378 220,304 268,334 278,776 185,534 225,217 234,041 236,044 236,480 86,145               
        operating lease right-of-use asset
      		    13,370 52,842 91,397 129,074 153,671   12,428 49,117 84,933 119,926 141,705 36,115 71,211 105,352 138,538 35,398 69,795 103,252         
        operating lease liability
      		    13,370 52,842 91,397 129,074 140,300   12,428 49,117 84,933 119,926 141,705 36,115 71,211 105,352 138,538 35,398 69,795 103,252         
        long-term liabilities:
      		                               
        total long-term liabilities
      		   6,612,295 6,486,268 6,360,240 6,235,583 6,112,295 5,999,639 5,860,240 5,735,583 5,612,295 5,486,268 5,360,240 5,235,583 5,112,994 2,053,005               
        stockholders' equity:
      		                               
        long-term liabilities
      		                               
        operating lease liability, non-current
      		        13,371                       
        other assets
      		               11,551    11,551    11,551 11,551  11,551 11,551 7,997 53,023 555,505 
        paycheck protection program loan
      		               104,168 104,168 104,168              
        milestone payable
      		             5,000,000 5,000,000 5,000,000 5,000,000 5,000,000              
        other current liabilities
      		             6,025 9,038               12,313  
        liabilities and stockholders' (deficit) equity
      		                               
        stockholders' (deficit) equity:
      		                               
        total stockholders' (deficit) equity
      		              7,811,384 -3,214,623 -1,923,415               
        total liabilities and stockholders' (deficit) equity
      		              19,295,950 9,434,048 6,750,899               
        warrant liability
      		                          3,701,277 4,095,019    
        current portion of long-term debt
      		                            146,052 150,430 1,442,592 
        long-term debt
      		                            4,233,059 4,241,448 1,511,461 
        other long-term liabilities
      		                               
        liabilities, convertible preferred stock and stockholders’ equity
      		                               
        deferred rent expense
      		                              6,830 
        series a convertible preferred stock, 0.0001 par value...
      		                               
        stockholders’ equity
      		                               
        deficit accumulated during the development stage
      		                              -22,691,468 
        total stockholders’ equity
      		                              21,183,261 
        total liabilities, convertible preferred stock and stockholders’ equity
      		                              24,986,458 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 
                                 
          operating activities
        		                         
          net income
        		-1,312,390 -1,267,218 -1,579,820 -1,987,401 -1,693,907 -1,867,917 -2,243,070 -1,803,221 -2,013,864 -2,233,380 -2,173,665 -1,672,362 -1,969,452 -2,290,643 -2,605,495 -2,267,862 -2,129,105 -6,967,395 -1,790,309 -1,418,228 -1,628,065 -2,114,096 -1,965,266 -1,760,632 -1,519,468 
          adjustments to reconcile net income to net cash from operating activities:
        		                         
          stock-based compensation expense
        		131,587 126,578 254,029 281,639 281,758 280,140 284,572 354,972 355,752 366,924 381,061 454,200 463,995 399,411 561,348 476,867 478,574 362,955 310,162 318,855 331,303 344,841 378,959 378,203 380,062 
          non-cash interest expense
        		126,027                         
          non-cash lease expense
        		   13,370 39,472 38,556 37,676 24,597                  
          change in operating assets and liabilities:
        		                         
          accounts receivable
        		-19,515 -551,099 -778,833 560,833 -210,091 -336,511 -62,470 50,138 -309,327 53,267 -123,717 -73,027 -23,755 -70,616 -104,484           
          prepaid expenses and other current assets
        		227,486 299,916 222,045                       
          inventories
        		51,357 44,011 -106,936                       
          accounts payable and accrued expenses
        		-188,084 242,624 343,596                     23,776 344,743 
          accrued compensation
        		164,837 159,916 -1,058,129 494,341 216,737 212,681 -190,907 -125,836 188,328 116,467 -107,119 -291,473 189,314 192,682 -587,438           
          operating lease liabilities
        		   -13,370 -39,472 -38,556 -37,676 -24,597                  
          net cash from operating activities
        		-818,695 -820,615 -2,579,390 -1,106,104 -1,041,605 -1,206,373 -1,630,895 -2,506,325 -1,100,925 -1,373,707 -1,615,030 -1,997,198 -5,892,138 -1,510,489 -2,953,119 -1,711,504 -1,810,528 -1,556,080 -1,551,895 -1,147,690 -1,059,090 -1,628,427 -1,926,886 -1,248,914 -1,149,938 
          capital expenditures
        		0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
          free cash flows
        		-818,695 -820,615 -2,579,390 -1,106,104 -1,041,605 -1,206,373 -1,630,895 -2,506,325 -1,100,925 -1,373,707 -1,615,030 -1,997,198 -5,892,138 -1,510,489 -2,953,119 -1,711,504 -1,810,528 -1,556,080 -1,551,895 -1,147,690 -1,059,090 -1,628,427 -1,926,886 -1,248,914 -1,149,938 
          financing activities
        		                         
          proceeds from february 2024 offering, net of issuance costs
        		0 -1 6,718,212                       
          payment of february 2024 offering costs
        		0 0 -426,293                       
          proceeds from march 2024 warrant amendment, net of issuance costs
        		                         
          proceeds from june 2024 warrant amendment, net of issuance costs
        		                         
          payment of august 2024 shelf registration statement offering costs
        		                         
          proceeds from september 2024 exercise price warrant amendment, net of issuance costs
        		                         
          proceeds from september 2024 warrant amendment, net of issuance costs
        		                         
          proceeds from exercise of pre-funded warrants
        		                         
          redemption of fractional shares due to reverse stock split
        		                         
          net cash from financing activities
        		2,979,891 295,696 7,542,719     0 0 7,123,455 171,521 0 313,107 45,454 13,070,154 3,499,787 100,792 5,413,284 21,250 306,721 123,813 5,039,956 636,432 0 1,186,777 
          net increase in cash and cash equivalents
        		2,161,196 -524,919 4,963,329     -2,506,325 -1,100,925 5,749,748 -1,443,509 -1,997,198 -5,579,031 -1,465,035 10,117,035 1,788,283 -1,709,736   -840,969 -935,277    36,839 
          cash and cash equivalents at beginning of period
        		0 0 4,739,426 0 0 0 9,843,699 0 0 0 9,144,710 0 0 0 8,068,939 0 0 0 5,663,833 0 0 0 5,319,004 0 0 
          cash and cash equivalents at end of period
        		2,161,196 -524,919 9,702,755 -1,225,400 -1,041,605 -1,206,373 8,212,804 -2,506,325 -1,100,925 5,749,748 7,701,201 -1,997,198 -5,579,031 -1,465,035 18,185,974 1,788,283 -1,709,736 3,857,204 4,133,188 -840,969 -935,277 3,411,529 4,028,550 -1,248,914 36,839 
          supplemental disclosure of non-cash financial activities
        		                         
          august 2024 shelf registration statement costs included in accounts payable and accrued expenses
        		                         
          september 2024 exercise price warrant amendment costs included in accounts payable and accrued expenses
        		                         
          september 2024 warrant amendment costs included in accounts payable and accrued expenses
        		                         
          raw materials
        		-25,816 0 283,283                       
          finished goods
        		-25,541 168,456 93,026                       
          total inventories
        		-51,357 -44,011 588,776                       
          proceeds from amendment and exercise of series b warrants, net of issuance costs
        		 295,697 1,250,800                       
          warrant amendment costs included in accounts payable and accrued expenses
        		                         
          interest expense
        		  124,658                       
          supplemental disclosure of non-cash financing activities
        		                         
          offering costs included in accounts payable
        		  20,926                       
          work in process
        		  212,467                       
          prepaid expenses and other assets
        		               -658,386 -193,579 228,042 227,089 229,299 -631,471 143,197 142,299 109,739 -355,275 
          inventory
        		                         
          accrued interest payable
        		                         
          proceeds from issuance of common stock from atm
        		       0   171,521 0              
          payment of atm offering costs
        		                         
          cash paid for offering costs
        		                         
          net cash (used)/provided by financing activities
        		                         
          net (decrease)/ increase in cash and cash equivalents
        		                         
          non-cash financing activities
        		                         
          public offering costs included in accounts payable and accrued expenses
        		                         
          operating lease right-of-use asset obtained in exchange for operating lease liabilities
        		                         
          common stock options
        		   -15,369 -6,000 76,250 569,351 0 0 -4,921,615 5,413,466 -136,874 -377,374 135,448 5,392,259 -195,806 -13,306 297,000 3,989,371 0 -118,500 -439,753 3,672,624 0 0 
          total excluded securities
        		   -15,369 -6,000 76,250 569,351 0 0 -4,933,615 5,425,466 -136,874 -539,580 135,448 7,234,138 -188,280 -547,267 -60,719 6,727,646 17,706 -111,206 -445,879 6,392,311 26,879 -130,612 
          prepaid expenses, inventory and other assets
        		    255,737 151,193 206,079  343,521 318,355 227,100  352,046 344,250 359,617           
          accounts payable and other accrued expenses
        		                         
          accrued interest expense
        		    126,028 124,657 123,288 126,027 126,028 124,657 123,288 125,065 126,028 125,619 122,589           
          payment of common stock offering costs from atm
        		                         
          net (decrease)/increase in cash and cash equivalents
        		                         
          supplemental disclosure of non-cash investing and financing activities
        		                         
          operating lease right-of-use assets obtained in exchange for operating lease liabilities
        		                         
          accounts payable and other current liabilities
        		     229,384 251,613 -86,378 208,637 -119,997 58,022 307,773 -30,314 -201,192 -604,126  -19,860 -179,682 -298,837  869,143 -2,369 -482,878   
          net decrease in cash and cash equivalents
        		     -1,206,373 -1,630,895            -1,530,645    -1,290,454   
          warrants to purchase common stock
        		          12,000 0 -162,206 0 1,841,879 0 -478,598 -393,084 2,713,561 0 0 0 2,713,561 0 -84,000 
          reserve for obsolete inventory
        		                         
          forgiveness of paycheck protection loan and accrued interest
        		           0 0 -962 -104,168           
          milestone payable
        		           0              
          proceeds from issuance of common stock
        		           0 0    -21,250 3,309,116 21,250 306,721 123,813 5,039,956 636,432 0 1,186,777 
          payment of common stock offering costs
        		                         
          proceeds from issuance of common stock from exercise of stock options
        		            0             
          deferred rent expense
        		              9,038           
          proceeds from issuance of common stock from employee stock purchase plan
        		               1          
          proceeds from issuance of common stock from stock options exercises
        		                         
          proceeds from paycheck protection program
        		               0 0         
          proceeds from eversana line of credit
        		               3,000,000 0         
          employee stock purchase plan
        		               7,526 -55,363 35,365 24,714 17,706   6,126 8,088 -16,447 
          proceeds from issuance of common stock, net of cost of 1,304,846
        		              13,070,154           
          accounts payable and accrued liabilities
        		                         
          milestone expense
        		                0         
          accrued interest
        		                         
          proceeds from issuance of common stock from stock option exercised
        		                         
          change in fair value of warrant liability
        		                       0 0 
          reclassification of warrant liability to equity due to amendment of warrants
        		                       0 0 
          common stock subject to repurchase
        		                         
          reclassification of warrant liability to equity due to exercise of warrants
        		                         
          non-cash interest
        		                         
          financing costs allocated to warrant liability
        		                         
          payment on bank loan
        		                         
          proceeds from issuance of common stock and warrants
        		                         
          supplemental disclosure of cash flow information
        		                         
          interest paid
        		                         
          fair value of warrants issued to placement agent
        		                         
          deferred financing costs paid in prior year
        		                         
          proceeds from bank line of credit
        		                         
          payment on bank line of credit
        		                         
          costs paid in connection with loan origination
        		                         
          cash paid for interest
        		                         
          non-cash financing activities deferred financing costs paid in prior year
        		                         
          other assets
        		                         
          issuance of series a convertible preferred stock warrants
        		                         
          conversion of series a convertible preferred stock to common stock at the initial public offering
        		                         
          change in fair value of purchase right liability
        		                         
          proceeds from convertible promissory note
        		                         
          proceeds from bank line of credit and loan advances
        		                         
          proceeds from issuance of preferred stock and purchase rights
        		                         
          proceeds from exercise of stock options
        		                         
          supplemental disclosures of cash flow information
        		                         
          conversion of convertible promissory note and accrued interest to series a convertible preferred stock
        		                         
          gross proceeds
        		                         
          underwriting discounts and commissions and non-accountable expense allowance
        		                         
          total offering costs
        		                         
          net proceeds